The global pharmaceutical industry strives to build an inclusive partner ecosystem that integrates technology, data, and regulatory standardization-enabled innovation into clinical trial delivery. This transformation aims to reduce the burden on investigators and sites while improving the efficiency and accuracy of adverse event (AE) tracking. Driven by the growing volume of adverse event reports, diverse datasets from disparate sources, the advent of digital technologies and tools, and the need for patient inclusivity in safety monitoring and reporting is resulting in a 10.4% CAGR across the global PV and safety testing services industry. The global pharmacovigilance and safety testing services industry was valued at $6.92 billion in 2024 and is expected to reach $12.49 billion by 2030.

While the industry is seeing technology convergence through the advent of cloud-based technologies (apart from pure play tech vendors that act as key enablers for technology-enabled PV services), eClinical solution vendors have also developed unique PV platforms to support adverse event data capture. For CROs, pharmaceutical companies, and drug regulatory agencies, technology licensing is the go-to option for adopting these solutions, making these companies potential partners.

• How can organizations leverage technology, data, and regulatory standardization to transform clinical trial delivery while reducing the burden on investigators and improving the accuracy of adverse event (AE) tracking?
• What growth opportunities exist for contract research organizations (CROs), pharma companies, and drug regulators in leveraging technology licensing to adopt technology-enabled PV services?
• How are PV vendors emphasizing regulatory affairs, data management services, and stakeholder interaction to drive industry growth?